What Chipscreen does

Chipscreen (微芯生物, SSE STAR Market: 688321) is a Shenzhen-headquartered, publicly-listed biopharmaceutical company founded in 2001 by a US-returnee scientific team led by Dr. Lu Xianping. The company specializes in the discovery and development of first-in-class small-molecule therapeutics across oncology and metabolic disease, anchored on a chemogenomics-integrated drug discovery platform that combines proprietary micro-array gene-chip experimentation with AI-assisted molecular design (via a 2022 collaboration with Huawei Cloud's Pangu model). Chipscreen operates a fully-integrated value chain from target identification through GMP manufacturing, with three marketed products: Chidamide (西达本胺 / Epidaza, the world's first subtype-selective HDAC inhibitor, approved in China, Japan, Taiwan, and Macau for PTCL, breast cancer and DLBCL), Chiglitazar (西格列他钠 / Bilessglu, the world's first PPAR pan-agonist for type 2 diabetes, approved in China and Macau), and Chiauranib (西奥罗尼, a multi-target kinase inhibitor currently in Phase III for small cell lung cancer).

Chipscreen monetizes through three complementary streams: (i) domestic prescription-drug revenue from the two marketed brands sold through its in-house commercialization team (covering hematology-oncology, breast and endocrinology departments) supplemented by an exclusive co-promotion with Haizheng Pharmaceutical across 19 Chinese provinces for Chiglitazar; (ii) out-licensing economics for Chidamide — upfront fees, milestone payments, and royalties via a 2006-vintage partnership with HUYA Bioscience International covering the US, Japan, and EU; and (iii) supply-side control via wholly-owned subsidiaries (Chengdu Chipscreen Pharma, Pengzhou Chipscreen Pharma, Chipscreen Biosciences USA, Chengdu Chipscreen New Horizon Biotech for next-gen biologics/ADCs). The pipeline contains 9 clinical-stage assets and 7 new molecular entities in research, with growing depth in kinase inhibitors (CS231295 brain-penetrant Aurora B, CS08399 PRMT5-MTA), autoimmune targets (CS32582 TYK2 for psoriasis), metabolic/obesity (CDCS28 non-GLP-1), and ADC biologics.

The customer base is fragmented across thousands of hospitals and end-patients, with no single hospital or payor representing material concentration. Indirect concentration exists via commercial partners (Haizheng for Chiglitazar in 19 provinces; HUYA for ex-China; BMS/BeiGene/Akeso/Ascletis for combination-trial supply), but the company retains product ownership. Pricing is anchored to China's National Reimbursement Drug List (NRDL) — Chidamide is in Category B, Chiglitazar has been added to the national formulary — implying volume-based rather than price-based upside, with specific transaction prices undisclosed.

Name

Chipscreen

Legal name

深圳微芯生物科技股份有限公司

Website

https://chipscreen.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Chipscreen (微芯生物, 688321.SH) is a Shenzhen-based, publicly-listed Chinese biopharmaceutical company founded in 2001 that discovers and develops first-in-class small-molecule drugs — notably Chidamide (HDAC inhibitor) and Chiglitazar (PPAR pan-agonist) — for oncology and metabolic disease, using an integrated chemogenomics plus AI-assisted design platform.

Ownership category

akta.pro rank

Product category

Innovative Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Small molecule drugs
• Innovative pharmaceuticals
• Oncology therapeutics
• Epigenetic drugs
• Drug discovery platform

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. 原创新药商业化销售: 两款原创新药西达本胺（爱谱沙）和西格列他钠（双洛平）在中国大陆市场的处方药销售，西达本胺已纳入国家医保药品目录常规乙类管理。2025年西格列他钠销售收入同比增长约123%。两款药物已在中国澳门获批上市，正在开拓更广泛的国际市场。
2. 专利技术授权许可（海外权益）: 通过'许可费+里程碑收入+收益分成'的专利技术授权许可方式，将西达本胺在美国、日本、欧盟等国家的权利授权给沪亚生物国际有限责任公司（HUYA Bioscience International），由其共同推进西达本胺在不同适应症领域的全球同步开发与商业化。2006年实现中国原创新药首个专利海外授权许可的先河。西达本胺已获日本PMDA批准上市。
3. 区域推广合作分成: 将西格列他钠在中国19个省份区域的推广权独家授予海正药业，公司保留产品所有权和生产能力，由海正药业提供专业学术推广服务，形成合作分成模式。

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Chipscreen (微芯生物) is a Chinese biopharmaceutical company specializing in the original discovery and development of small molecule drugs. The company develops innovative therapeutics for oncology and metabolic diseases, including the HDAC inhibitor Chidamide, the PPAR pan-agonist Chiglitazar, and the multi-target kinase inhibitor Chiauranib, leveraging proprietary AI-assisted drug design and chemogenomics technology platforms.

Product overview

Chipscreen (微芯生物) is a Chinese biopharmaceutical company pioneering original drug discovery. The company operates a technology platform combining AI-assisted design with chemogenomics for drug development. Its core product portfolio includes three marketed drugs: 西达本胺 (Chidamide, an HDAC inhibitor for oncology), 西格列他钠 (Chiglitazar, a PPAR pan-agonist for diabetes), and 西奥罗尼 (Chiauranib, a multi-target kinase inhibitor in Phase III for oncology). The company has an extensive pipeline including CS231295 (brain-penetrating Aurora B inhibitor), CS08399 (PRMT5-MTA inhibitor), CS32582 (TYK2 inhibitor for psoriasis), and multiple ADC candidates (NW008, NW024-1, NW006-296). A novel formulation combining 西格列他钠 with metformin is also in development. Chipscreen develops drugs across five major therapeutic areas: oncology, metabolic diseases, autoimmune diseases, neurodegenerative diseases, and antiviral infections.

Differentiator

Problem solved

Functional benefit

Brands

• Epidaza®/爱谱沙®: Brand name for Chidamide (西达本胺), a global first-in-class HDAC inhibitor for treatment of PTCL, breast cancer, and DLBCL.
• Bilessglu®/双洛平®

Products and services

• Chidamide (西达本胺, brand name: Epidaza)

Quantifiable outcome

• 西达本胺联合R-CHOP治疗DE-DLBCL：EFS风险降低28%（HR=0.72），CR率提升11.1%（73.0% vs 61.8%），死亡风险降低23%（HR=0.77），DEB研究结果发表于JAMA（IF=55）
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered minor, major, core and supporting.

• NizhpharmminorChannel Partner/ Reseller/ Distributor · 4 February 2026微芯生物与Nizhpharm签署许可及分销协议，扩展西达本胺在特定市场的商业化布局。
• 歌礼制药有限公司（Ascletis/1672.HK）minorStrategic or Co-development Partner · 4 July 2022合作方歌礼制药旗下上海市公共卫生临床中心发起PD-L1抗体ASC22（恩沃利单抗）联合西达本胺用于HIV感染者功能性治愈的临床研究已完成首例患者给药。西达本胺在体外实验以及小规模临床试验中显示了对潜伏的HIV感染细胞具有潜在的激活作用，与PD-L1抗体联合有望发挥更强大的HIV病毒储存库清除作用。
• 康方生物（Akeso/9926.HK）majorStrategic or Co-development Partner · 28 February 2022微芯生物与康方生物达成合作协议，共同开展PD-1/CTLA-4双特异性抗体卡度尼利（AK104）联合西奥罗尼治疗一线含铂化疗联合PD-(L)1抑制剂治疗方案进展的广泛期小细胞肺癌（ES-SCLC）的Ib/II期临床研究。西奥罗尼作为多通路选择性激酶抑制剂的独特性与卡度尼利肿瘤双免疫治疗的优势结合，期望为患者带来更有效的临床获益。
• HUYA Bioscience International（沪亚生物国际有限责任公司）coreOEM/ Whitelabel/ Licensing Partner · 30 March 2021微芯生物通过'许可费+里程碑收入+收益分成'的专利技术授权许可方式将西达本胺在美国、日本、欧盟等国家的权利授权许可给沪亚生物国际有限责任公司（HUYA），由其在海外市场共同推进西达本胺在不同适应症领域的全球同步开发与商业化。2006年实现中国原创新药首个专利海外授权许可的先河。西达本胺已在日本获批上市（治疗成人T细胞白血病），美国已完成II期临床并与BMS开展III期临床合作。
• Bristol Myers Squibb（百时美施贵宝/BMS）majorStrategic or Co-development Partner · 30 March 2021通过合作方沪亚（HUYA），与BMS就西达本胺（HBI-8000）与欧狄沃（纳武单抗/PD-1阻断抗体）开展联合治疗黑色素瘤的全球III期关键临床试验。沪亚是III期试验的发起者，施贵宝将为试验提供欧狄沃的临床药物供应。评估联合用药对先前未接受过抗PD-1治疗的不可切除或转移性黑色素瘤患者的有效性和安全性。
• 浙江海正药业股份有限公司coreChannel Partner/ Reseller/ Distributor · 16 December 2020微芯生物将自主研发并由旗下全资子公司成都微芯药业有限公司生产的西格列他钠片（双洛平）在中国19个省份区域的推广权独家授予海正药业，本合作旨在为中国患者快速提供创新机制的糖尿病治疗药物，微芯生物仍然是该产品的所有者和生产者，由海正药业提供专业的学术推广、营销及网络覆盖，共同制定市场策略、完成学术推广、品牌管理等一体式的集成服务。
• 百济神州（Baijiu/ZPNT）minorStrategic or Co-development Partner西达本胺联合替雷利珠单抗（BGB-A317，PD-1抑制剂）治疗非小细胞肺癌获批开展II期临床试验。替雷利珠单抗是由百济神州的免疫肿瘤生物平台研发的候选药物，属于免疫检查点抑制剂，与西达本胺联合评估对PD-L1表达阳性的局部晚期或转移性非小细胞肺癌患者的疗效与安全性。
• 成都市药物警戒和风险管理研究院minorOthers微芯生物与深圳市药物警戒和风险管理研究院签署深化合作备忘录，围绕创新药品种评价、真实世界数据应用研究及慢病用药长期监测等方面开展深度协作，共同探索利用真实世界数据赋能药物警戒科学的新路径。
• 华为云supportingTechnology or Integration2022年微芯与华为云合作，利用华为盘古大模型实现辅助药物分子设计，有效补足了蛋白质-药物相互作用等部分，为原创新药全链条独立、自主开发的闭环提供极大帮助。通过综合运用平台靶点口袋发现、分子对接、分子生成与优化、分子属性预测等AI能力，提高早期发现阶段效率。

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• HUTCHMED (China) Limited: Hong Kong and US-listed Chinese biopharma developing first-in-class small molecule oncology drugs (e.g., surufatinib, savolitinib) with global out-licensing. Highly comparable to Chipscreen in origin (China-originated), focus (small molecule innovators), and international partnership model.
• Akeso, Inc. (康方生物): HK-listed Chinese biotech known for first-in-class bispecific antibodies (e.g., cadonilimab/AK104) and an active partner of Chipscreen on Chiauranib combinations. Comparable in innovative drug focus, China-originated pipeline, and combination therapy strategy.
• Zai Lab Limited: US/HK-listed Chinese biopharma that licenses and develops innovative oncology and autoimmune drugs for the China market, with growing in-house discovery. Comparable to Chipscreen in clinical-stage portfolio, focus on innovative oncology, and global capital markets presence.
• Junshi Biosciences (君实生物): HK and STAR Market-listed Chinese biotech with commercialized toripalimab (PD-1) and an innovative pipeline. Comparable in STAR Market listing, innovative drug focus, and combination therapy interest with epigenetic and small molecule partners.
• Innovent Biologics, Inc. (信达生物): HK-listed Chinese biotech with multiple commercialized innovative biologics and a deep oncology pipeline. Comparable to Chipscreen in scale, China-originated innovation, multi-product commercial portfolio, and partnership-heavy go-to-market.
• Cstone Pharmaceuticals (基石药业): HK-listed Chinese biopharma with multiple commercialized oncology assets (e.g., avapritinib, sugemalimab) and in-house discovery. Comparable to Chipscreen in China-originated innovation, oncology focus, and partnership-led commercialization.

Broad incumbents

• BeiGene, Ltd. Global oncology leader with the PD-1 inhibitor tislelizumab (a competitive combination partner for Chidamide) and BTK inhibitor zanubrutinib. Comparable to Chipscreen as a China-originated innovative oncology company with global commercial footprint, though at a substantially larger scale.
• Jiangsu Hengrui Pharmaceuticals (恒瑞医药): Largest China-listed innovative pharma with broad oncology, anesthesia, and metabolic portfolios and significant small molecule R&D capability. Comparable in Chinese innovative drug focus, but at a substantially larger scale and broader therapeutic coverage.

Others

• BeiGene's Maplarex / HUYA Bioscience International: HUYA is Chipscreen's existing US/Japan/EU licensing partner for Chidamide and a co-developer of the US Phase III with BMS. Included as an ecosystem participant and licensing counterparty rather than a direct competitor.

Emerging players

• Ascletis Pharma (歌礼制药): HK-listed Chinese biotech with a focus on antiviral and metabolic diseases, and a direct co-development partner with Chipscreen on Chidamide for HIV functional cure. Comparable in Chinese innovative drug focus and metabolic/antiviral pipeline overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries6 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chipscreen